Search results
Results from the WOW.Com Content Network
The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible ...
The main discussion of these abbreviations in the context of drug prescriptions and other medical prescriptions is at List of abbreviations used in medical prescriptions. Some of these abbreviations are best not used, as marked and explained here.
take (often effectively a noun meaning "prescription"—medical prescription or prescription drug) rep. repetatur: let it be repeated s. signa: write (write on the label) s.a. secundum artem: according to the art (accepted practice or best practice) SC subcutaneous "SC" can be mistaken for "SL," meaning sublingual. See also SQ: sem. semen seed
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
For premium support please call: 800-290-4726 more ways to reach us
The Medicaid Drug Rebate Program provides for mandatory rebates on innovator drugs (e.g., brand drugs), blood clotting factors, drugs Food and Drug Administration-approved exclusively for pediatric indications, and non-innovator drugs (e.g., generic drugs). [1] The maximum rebate is capped at 100% of the Average Manufacturer Price (AMP).
340B Drug Program is applicable to hospitals (mixed-use and outpatient clinics) and contract pharmacies. The 340B Program is often managed by software for maximizing the savings and for providing compliance. 340BSoftware.com is an example of such software. The Program is a federal program.
Faster drug approval times and other PDUFA-related changes have led to pharmaceutical companies targeting more drugs for first launch in the United States thus increasing patient access to new medicines. Faster drug review from 1990 to 2001 were found to increase the probability of a drug being launched first in the United States by 14%.